With greater focus on improving outcomes and reducing cost in healthcare, there has been a significant push across the sector to link payment with performance through risk sharing or similar value-based agreements.  Although manufacturers have been largely unaffected by these agreements thus far, recent trends suggest a shift.

In light of mounting drug prices, payers and providers are becoming increasingly resistant to drugs and therapies where compelling economic and clinical value can’t be demonstrated.  At the same time, patients are asking more questions as they assume more financial responsibility for their healthcare costs.  We’ve highlighted the key considerations for manufacturers in our article, Considerations for Risk Sharing Agreements, published by eyeforpharma.